BB Biotech AG Adjusts Stake in Ionis Pharmaceuticals
| NBIX Stock | USD 118.92 9.17 8.36% |
Slightly above 55% of Neurocrine Biosciences' investors are presently thinking to get in. The analysis of overall sentiment of trading Neurocrine Biosciences stock suggests that some investors are interested at this time. Neurocrine Biosciences' investing sentiment can be driven by a variety of factors including economic data, Neurocrine Biosciences' earnings reports, geopolitical events, and overall market trends.
Neurocrine | Build AI portfolio with Neurocrine Stock |
Overview of the Recent Transaction On September 30, 2024, BB Biotech AG, a prominent investment firm specializing in the biotechnology sector, executed a signif
Read at gurufocus.com
 |
Neurocrine Biosciences Fundamental Analysis
We analyze Neurocrine Biosciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Neurocrine Biosciences is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Neurocrine Biosciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neurocrine Biosciences stock to make a market-neutral strategy. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics with similar companies.
Peers
Neurocrine Biosciences Related Equities
| AVDL | Avadel Pharmaceuticals | 3.91 | ||||
| IRWD | Ironwood Pharmaceuticals | 2.20 | ||||
| SUPN | Supernus Pharmaceuticals | 0.12 | ||||
| ALKS | Alkermes Plc | 1.20 | ||||
| PBH | Prestige Brand | 2.35 | ||||
| PCRX | Pacira BioSciences, | 2.42 | ||||
| COLL | Collegium Pharmaceutical | 2.70 | ||||
| EVO | Evotec SE | 2.88 | ||||
| DVAX | Dynavax Technologies | 3.02 | ||||
| ANIP | ANI Pharmaceuticals | 3.16 | ||||
| AMPH | Amphastar | 4.98 |
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.